Emerging drugs for adrenocortical carcinoma

Background: Adrenocortical carcinoma (ACC) is an extremely rare aggressive disease. Few data are available on the efficacy of systemic antineoplastic treatments (mitotane and cytotoxic therapy) in the treatment of advanced disease. Objective/methods: this paper will review the existing treatment strategies and new perspectives in the management of ACC patients. Results/conclusion: An ongoing randomized international trial aims to define the best combination chemotherapy plus mitotane regimen. Based on the results of a case control study, mitotane is being explored as adjuvant therapy. Genetic and biological studies have identified molecular targets for specific targeted drugs such as IGF receptor inhibitors and antiangiogenetic drugs. Phase II trials are exploring the activity of these drugs either alone or in combination with chemotherapy.

[1]  G. Hammer,et al.  Management of adrenocortical carcinoma. , 2009, The Journal of the National Comprehensive Cancer Network.

[2]  P. Adam,et al.  Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. , 2008, The Journal of clinical endocrinology and metabolism.

[3]  A. Berruti,et al.  Adjunctive treatment of adrenocortical carcinoma , 2008, Current opinion in endocrinology, diabetes, and obesity.

[4]  R. Quinton,et al.  Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review , 2008, Journal of Clinical Pathology.

[5]  M. Papotti,et al.  Pathological and molecular features of adrenocortical carcinoma: an update , 2008, Journal of Clinical Pathology.

[6]  T. Hamilton,et al.  Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.

[7]  T. Abe,et al.  Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. , 2008, Endocrine journal.

[8]  J. Bertherat,et al.  Loss of Heterozygosity of 17p13, With Possible Involvement of ACADVL and ALOX15B, in the Pathogenesis of Adrenocortical Tumors , 2008, Annals of surgery.

[9]  G. Hammer,et al.  The molecular genetics of adrenocortical carcinoma , 2007, Reviews in Endocrine and Metabolic Disorders.

[10]  O. Nativ,et al.  Adjuvant mitotane in adrenocortical carcinoma. , 2007, The New England journal of medicine.

[11]  W. Oh,et al.  A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC) , 2007 .

[12]  M. Papotti,et al.  Adjuvant mitotane treatment for adrenocortical carcinoma. , 2007, The New England journal of medicine.

[13]  A. Phan.  Adrenal cortical carcinoma--review of current knowledge and treatment practices. , 2007, Hematology/oncology clinics of North America.

[14]  A. Latronico,et al.  The Molecular Pathogenesis of Childhood Adrenocortical Tumors , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[15]  J. Bertherat,et al.  Adrenocortical cancer: pathophysiology and clinical management. , 2007, Endocrine-related cancer.

[16]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[17]  J. Riedemann,et al.  IGF1R signalling and its inhibition. , 2006, Endocrine-related cancer.

[18]  J. Bertherat,et al.  Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. , 2006, The Journal of clinical endocrinology and metabolism.

[19]  A. Fojo,et al.  The efficacy of combination chemotherapy with cisplatin and gemcitabine in patients with advanced adrenal cortical carcinoma (ACC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Kirschner.  Emerging treatment strategies for adrenocortical carcinoma: a new hope. , 2006, The Journal of clinical endocrinology and metabolism.

[21]  T. Giordano,et al.  Management of patients with adrenal cancer: recommendations of an international consensus conference. , 2005, Endocrine-related cancer.

[22]  P. Casali,et al.  Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. , 2005, Endocrine-related cancer.

[23]  M. Fassnacht,et al.  Mitotane for adrenocortical carcinoma treatment. , 2005, Current opinion in investigational drugs.

[24]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[25]  R. Callaghan,et al.  Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy. , 2004, European journal of cancer.

[26]  D. Schteingart.  Current Perspective in the Diagnosis and Treatment of Adrenocortical Carcinoma , 2001, Reviews in Endocrine and Metabolic Disorders.

[27]  Adrian L Harris,et al.  Angiogenesis in endocrine tumors. , 2003, Endocrine reviews.

[28]  M. Latorre,et al.  Adrenocortical tumours in children and adults: a study of pathological and proliferation features , 2003, Pathology.

[29]  P. Miccoli,et al.  Angiogenesis in human normal and pathologic adrenal cortex. , 2002, The Journal of clinical endocrinology and metabolism.

[30]  S. Steinberg,et al.  A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma , 2002, Cancer.

[31]  C. Cordon-Cardo,et al.  Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  W. Mcdougal.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. , 2002, The Journal of urology.

[33]  P. Choyke,et al.  A Phase I study of infusional vinblastine in combination with the p‐glycoprotein antagonist PSC 833 (valspodar) , 2001, Cancer.

[34]  E. Baudin,et al.  Impact of monitoring plasma 1,1‐dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma , 2001, Cancer.

[35]  P. Schultz,et al.  Adrenocortical carcinoma , 2001, Cancer.

[36]  C. Stratakis,et al.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Y. Chapuis,et al.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group , 2001, World Journal of Surgery.

[38]  S. Lindstedt,et al.  Cytotoxic treatment of adrenocortical carcinoma , 2001, World Journal of Surgery.

[39]  P. De Giuli,et al.  Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. , 2001, Urology.

[40]  P. Charlton,et al.  In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. , 2001, Cancer research.

[41]  X. Bertagna,et al.  Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations. , 2000, The Journal of clinical endocrinology and metabolism.

[42]  C. Juhlin,et al.  Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  A. Kasperlik-Załuska.  Clinical results of the use of mitotane for adrenocortical carcinoma. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[44]  L. Dogliotti,et al.  Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[45]  G. Miller,et al.  Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma , 2000, Cancer.

[46]  A. Latronico,et al.  Adrenocortical carcinoma , 2000, Cancer.

[47]  D. Vittet,et al.  Paracrine Control of the Adult Adrenal Cortex Vasculature by Vascular Endothelial Growth Factor , 2000, Endocrine research.

[48]  M. Brennan,et al.  Long-Term Survival After Complete Resection and Repeat Resection in Patients With Adrenocortical Carcinoma , 1999, Annals of Surgical Oncology.

[49]  C. Higgins,et al.  The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein , 1999, British journal of pharmacology.

[50]  V. Budach,et al.  [Adrenal cortical carcinoma]. , 1999, Zhonghua wai ke za zhi [Chinese journal of surgery].

[51]  P. Gaudin,et al.  Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. , 1999, Archives of surgery.

[52]  N. Zaffaroni,et al.  Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells. , 1999, International journal of oncology.

[53]  L. Dogliotti,et al.  Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma , 1998, Cancer.

[54]  E. Baudin,et al.  Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Réseau Comète INSERM. , 1998, British Journal of Cancer.

[55]  F. Mosca,et al.  Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. , 1997, Surgery.

[56]  M. Boscaro,et al.  Adrenocortical carcinoma: experience in 45 patients. , 1997, Oncology.

[57]  W. Kiess,et al.  Insulin-like growth factor receptors in normal and tumorous adult human adrenocortical glands. , 1997, European journal of endocrinology.

[58]  R. Bellantone,et al.  The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. , 1996, Surgery.

[59]  D. Berger,et al.  Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. , 1995, Surgery.

[60]  G. Fleuren,et al.  Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. , 1994, British Journal of Cancer.

[61]  D. Palli,et al.  Epidemiology of intestinal and diffuse types of gastric carcinoma: a time-trend study in Finland with comparison between studies from high- and low-risk areas. , 1994, Cancer.

[62]  K. Hess,et al.  Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer , 1993, Cancer.

[63]  M. Wooten,et al.  Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature , 1993, Cancer.

[64]  J. Goldblum,et al.  Immunohistochemical assessment of proliferative activity in adrenocortical neoplasms. , 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[65]  V. Ilvesmäki,et al.  Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. , 1993, The Journal of clinical endocrinology and metabolism.

[66]  K. Hess,et al.  Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer , 1993, Cancer.

[67]  R. Bukowski,et al.  Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M. Brennan,et al.  An eleven-year experience with adrenocortical carcinoma. , 1992, Surgery.

[69]  T. Hogan,et al.  Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. , 1991, Surgery.

[70]  A. Gazdar,et al.  Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. , 1991, The Journal of clinical endocrinology and metabolism.

[71]  M. Schlumberger,et al.  5‐Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma , 1991, Cancer.

[72]  E. Chambaz,et al.  Transforming growth factor beta 1: an autocrine regulator of adrenocortical steroidogenesis. , 1991, Endocrine research.

[73]  P Blondeau,et al.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. , 1990, The New England journal of medicine.

[74]  L. Medeiros,et al.  Pathologic Features of Prognostic Significance in Adrenocortical Carcinoma , 1989, The American journal of surgical pathology.

[75]  J. Montie,et al.  The Cleveland Clinic experience with adrenal cortical carcinoma. , 1989, The Journal of urology.

[76]  A. Baird,et al.  Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[77]  H. V. van Slooten,et al.  The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. , 1984, European journal of cancer & clinical oncology.

[78]  P. Carpenter,et al.  Adrenal cortical carcinoma--a continuing challenge. , 1983, Surgery.

[79]  A. V. van Oosterom,et al.  CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. , 1983, Cancer treatment reports.

[80]  N. Thompson,et al.  Treatment of adrenal carcinomas. , 1982, Archives of surgery.

[81]  D. A. Macfarlane.  Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. , 1958, Annals of the Royal College of Surgeons of England.